|
1
|
Cornford P, Bellmunt J, Bolla M, Briers E,
De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, et al:
EAU-ESTRO-SIOG Guidelines on prostate cancer. Part II: Treatment of
relapsing, metastatic, and castration-resistant prostate cancer.
Eur Urol. 71:630–642. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lowrance WT, Roth BJ, Kirkby E, Murad MH
and Cookson MS: Castration-resistant prostate cancer: AUA Guideline
Amendment 2015. J Urol. 195:1444–1452. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Crawford ED, Higano CS, Shore ND, Hussain
M and Petrylak DP: Treating patients with metastatic castration
resistant prostate cancer: A comprehensive review of available
therapies. J Urol. 194:1537–1547. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Qiu J, Jiang W, Yang Y, Feng C, Chen Z,
Guan G, Zhuo S and Chen J: Monitoring changes of tumor
microenvironment in colorectal submucosa using multiphoton
microscopy. Scanning. 37:17–22. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Casey SC, Amedei A, Aquilano K, Azmi AS,
Benencia F, Bhakta D, Bilsland AE, Boosani CS, Chen S, Ciriolo MR,
et al: Cancer prevention and therapy through the modulation of the
tumor microenvironment. Semin Cancer Biol. 35 Suppl:S199–S223.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wolff M, Kosyna FK, Dunst J, Jelkmann W
and Depping R: Impact of hypoxia inducible factors on estrogen
receptor expression in breast cancer cells. Arch Biochem Biophys.
613:23–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu X, Qiao B, Liu Q and Zhang W:
Upregulation of extracellular matrix metalloproteinase inducer
promotes hypoxia-induced epithelial-mesenchymal transition in
esophageal cancer. Mol Med Rep. 12:7419–7424. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Clavo B, Robaina F, Fiuza D, Ruiz A,
Lloret M, Rey-Baltar D, Llontop P, Riveros A, Rivero J, Castañeda
F, et al: Predictive value of hypoxia in advanced head and neck
cancer after treatment with hyperfractionated radio-chemotherapy
and hypoxia modification. Clin Transl Oncol. 19:419–424. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li W, Dong Y, Zhang B, Kang Y, Yang X and
Wang H: PEBP4 silencing inhibits hypoxia-induced
epithelial-to-mesenchymal transition in prostate cancer cells.
Biomed Pharmacother. 81:1–6. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li M, Wang YX, Luo Y, Zhao J, Li Q, Zhang
J and Jiang Y: Hypoxia inducible factor-1α-dependent epithelial to
mesenchymal transition under hypoxic conditions in prostate cancer
cells. Oncol Rep. 36:521–527. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang W, Liu M, Guan Y and Wu Q:
Hypoxia-responsive Mir-301a and Mir-301b promote radioresistance of
prostate cancer cells via downregulating NDRG2. Med Sci Monit.
22:2126–2132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nomura T, Yamasaki M, Hirai K, Inoue T,
Sato R, Matsuura K, Moriyama M, Sato F and Mimata H: Targeting the
Vav3 oncogene enhances docetaxel-induced apoptosis through the
inhibition of androgen receptor phosphorylation in LNCaP prostate
cancer cells under chronic hypoxia. Mol Cancer. 12:272013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Barsoum IB, Koti M, Siemens DR and Graham
CH: Mechanisms of hypoxia-mediated immune escape in cancer. Cancer
Res. 74:7185–7190. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hasmim M, Noman MZ, Messai Y, Bordereaux
D, Gros G, Baud V and Chouaib S: Cutting edge: Hypoxia-induced
Nanog favors the intratumoral infiltration of regulatory T cells
and macrophages via direct regulation of TGF-β1. J Immunol.
191:5802–5806. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Noman MZ, Buart S, Romero P, Ketari S,
Janji B, Mari B, Mami-Chouaib F and Chouaib S: Hypoxia-inducible
miR-210 regulates the susceptibility of tumor cells to lysis by
cytotoxic T cells. Cancer Res. 72:4629–4641. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu Y, Hu J, Sun W, Duan X and Chen X:
Hypoxia-mediated immune evasion of pancreatic carcinoma cells. Mol
Med Rep. 11:3666–3672. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yamada N, Yamanegi K, Ohyama H, Hata M,
Nakasho K, Futani H, Okamura H and Terada N: Hypoxia downregulates
the expression of cell surface MICA without increasing soluble MICA
in osteosarcoma cells in a HIF-1α-dependent manner. Int J Oncol.
41:2005–2012. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sarkar S, Germeraad WT, Rouschop KM,
Steeghs EM, van Gelder M, Bos GM and Wieten L: Hypoxia induced
impairment of NK cell cytotoxicity against multiple myeloma can be
overcome by IL-2 activation of the NK cells. PLoS One.
8:e648352013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Labiano S, Palazon A and Melero I: Immune
response regulation in the tumor microenvironment by hypoxia. Semin
Oncol. 42:378–386. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hamilton TK, Hu N, Kolomitro K, Bell EN,
Maurice DH, Graham CH and Siemens DR: Potential therapeutic
applications of phosphodiesterase inhibition in prostate cancer.
World J Urol. 31:325–330. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Siemens DR, Hu N, Sheikhi AK, Chung E,
Frederiksen LJ, Pross H and Graham CH: Hypoxia increases tumor cell
shedding of MHC class I chain-related molecule: Role of nitric
oxide. Cancer Res. 68:4746–4753. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Barsoum IB, Smallwood CA, Siemens DR and
Graham CH: A mechanism of hypoxia-mediated escape from adaptive
immunity in cancer cells. Cancer Res. 74:665–674. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen J, Jiang CC, Jin L and Zhang XD:
Regulation of PD-L1: A novel role of pro-survival signalling in
cancer. Ann Oncol. 27:409–416. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shi MH, Xing YF, Zhang ZL, Huang JA and
Chen YJ: Effect of soluble PD-L1 released by lung cancer cells in
regulating the function of T lymphocytes. Zhonghua Zhong Liu Za
Zhi. 35:85–88. 2013.(In Chinese). PubMed/NCBI
|
|
25
|
Akbay EA, Koyama S, Carretero J, Altabef
A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp
EM, Pugh TJ, et al: Activation of the PD-1 pathway contributes to
immune escape in EGFR-driven lung tumors. Cancer Discov.
3:1355–1363. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mahoney KM, Freeman GJ and McDermott DF:
The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in
melanoma. Clin Ther. 37:764–782. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mandai M, Hamanishi J, Abiko K, Matsumura
N, Baba T and Konishi I: Anti-PD-L1/PD-1 immune therapies in
ovarian cancer: Basic mechanism and future clinical application.
Int J Clin Oncol. 21:456–461. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bardoli AD, Afshar M, Viney R, Foster M,
Porfiri E, Zarkar A, Stevenson R, James ND, Bryan RT and Patel P:
The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder
cancer and evaluating its potential as a therapeutic target. Future
Oncol. 12:595–600. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brower V: Anti-PD-L1 antibody active in
metastatic bladder cancer. Lancet Oncol. 16:e112015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vassilakopoulou M, Avgeris M, Velcheti V,
Kotoula V, Rampias T, Chatzopoulos K, Perisanidis C, Kontos CK,
Giotakis AI, Scorilas A, et al: Evaluation of PD-L1 expression and
associated tumor-infiltrating lymphocytes in laryngeal squamous
cell carcinoma. Clin Cancer Res. 22:704–713. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yao S and Chen L: PD-1 as an immune
modulatory receptor. Cancer J. 20:262–264. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang BY, Zhan YP, Zong WJ, Yu CJ, Li JF,
Qu YM and Han S: The PD-1/B7-H1 pathway modulates the natural
killer cells versus mouse glioma stem cells. PLoS One.
10:e01347152015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Joo HY, Yun M, Jeong J, Park ER, Shin HJ,
Woo SR, Jung JK, Kim YM, Park JJ, Kim J and Lee KH: SIRT1
deacetylates and stabilizes hypoxia-inducible factor-1α (HIF-1α)
via direct interactions during hypoxia. Biochem Biophys Res Commun.
462:294–300. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Doi T, Ishikawa T, Okayama T, Oka K,
Mizushima K, Yasuda T, Sakamoto N, Katada K, Kamada K, Uchiyama K,
et al: The JAK/STAT pathway is involved in the upregulation of
PD-L1 expression in pancreatic cancer cell lines. Oncol Rep.
37:1545–1554. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bellucci R, Martin A, Bommarito D, Wang K,
Hansen SH, Freeman GJ and Ritz J: Interferon-γ-induced activation
of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells
through upregulation of PD-L1 expression. Oncoimmunology.
4:e10088242015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Atefi M, Avramis E, Lassen A, Wong DJ,
Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, et
al: Effects of MAPK and PI3K pathways on PD-L1 expression in
melanoma. Clin Cancer Res. 20:3446–3457. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang L, Huang F, Mei J, Wang X, Zhang Q,
Wang H, Xi M and You Z: Posttranscriptional control of PD-L1
expression by 17β-estradiol via PI3K/Akt signaling pathway in
ERα-positive cancer cell lines. Int J Gynecol Cancer. 27:196–205.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jiang X, Zhou J, Giobbie-Hurder A, Wargo J
and Hodi FS: The activation of MAPK in melanoma cells resistant to
BRAF inhibition promotes PD-L1 expression that is reversible by MEK
and PI3K inhibition. Clin Cancer Res. 19:598–609. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gowrishankar K, Gunatilake D, Gallagher
SJ, Tiffen J, Rizos H and Hersey P: Inducible but not constitutive
expression of PD-L1 in human melanoma cells is dependent on
activation of NF-κB. PLoS One. 10:e01234102015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hernandez RK, Cetin K, Pirolli M, Quigley
J, Quach D, Smith P, Stryker S and Liede A: Estimating high-risk
castration resistant prostate cancer (CRPC) using electronic health
records. Can J Urol. 22:7858–7864. 2015.PubMed/NCBI
|
|
41
|
Kamoto T: Evaluation and diagnosis for
castration resistant prostate cancer: CRPC. Nihon Rinsho.
72:2103–2107. 2014.(In Japanese). PubMed/NCBI
|
|
42
|
Walsh JC, Lebedev A, Aten E, Madsen K,
Marciano L and Kolb HC: The clinical importance of assessing tumor
hypoxia: Relationship of tumor hypoxia to prognosis and therapeutic
opportunities. Antioxid Redox Signal. 21:1516–1554. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jensen LD: The circadian clock and hypoxia
in tumor cell de-differentiation and metastasis. Biochim Biophys
Acta. 1850:1633–1641. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lanier LL: NKG2D receptor and its ligands
in host defense. Cancer Immunol Res. 3:575–582. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Swaika A, Hammond WA and Joseph RW:
Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.
Mol Immunol. 67:4–17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ohaegbulam KC, Assal A, Lazar-Molnar E,
Yao Y and Zang X: Human cancer immunotherapy with antibodies to the
PD-1 and PD-L1 pathway. Trends Mol Med. 21:24–33. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cai B, Cai JP, Luo YL, Chen C and Zhang S:
The specific roles of JAK/STAT signaling pathway in sepsis.
Inflammation. 38:1599–1608. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Teng Y, Ross JL and Cowell JK: The
involvement of JAK-STAT3 in cell motility, invasion, and
metastasis. JAKSTAT. 3:e280862014.PubMed/NCBI
|
|
49
|
O'Shea JJ, Holland SM and Staudt LM: JAKs
and STATs in immunity, immunodeficiency, and cancer. N Engl J Med.
368:161–170. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang SW and Sun YM: The IL-6/JAK/STAT3
pathway: Potential therapeutic strategies in treating colorectal
cancer (Review). Int J Oncol. 44:1032–1040. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Liu RY, Zeng Y, Lei Z, Wang L, Yang H, Liu
Z, Zhao J and Zhang HT: JAK/STAT3 signaling is required for
TGF-β-induced epithelial-mesenchymal transition in lung cancer
cells. Int J Oncol. 44:1643–1651. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lapeire L, Hendrix A, Lambein K, Van
Bockstal M, Braems G, Van Den Broecke R, Limame R, Mestdagh P,
Vandesompele J, Vanhove C, et al: Cancer-associated adipose tissue
promotes breast cancer progression by paracrine oncostatin M and
Jak/STAT3 signaling. Cancer Res. 74:6806–6819. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Duzagac F, Inan S, Simsek Ela F, Acikgoz
E, Guven U, Khan SA, Rouhrazi H, Oltulu F, Aktug H, Erol A and
Oktem G: JAK/STAT pathway interacts with intercellular cell
adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM)
while prostate cancer stem cells form tumor spheroids. J BUON.
20:1250–1257. 2015.PubMed/NCBI
|
|
54
|
Kim JM and Chen DS: Immune escape to
PD-L1/PD-1 blockade: Seven steps to success (or failure). Ann
Oncol. 27:1492–1504. 2016. View Article : Google Scholar : PubMed/NCBI
|
